PAR-25-139-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) grant opportunity, solicitation number PAR-25-139, issued by the National Institutes of Health (NIH).

The grant opportunity supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies. The R21 mechanism provides support for the early and conceptual stages of these projects, which may involve considerable risk but could lead to breakthroughs or novel techniques, agents, methodologies, models, or applications. Eligible applicants include 501(c)(3) nonprofits, higher education institutions, governments, small businesses, and others. The grant opportunity is funded under several NIH grant programs, including Cancer Detection and Diagnosis Research, Cancer Treatment Research, Cancer Cause and Prevention Research, Cancer Control, and Cancer Biology Research.